about
Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.PfCRT and PfMDR1 modulate interactions of artemisinin derivatives and ion channel blockersSelective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory siteLarge-scale pharmacological profiling of 3D tumor models of cancer cells.High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinationsRNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription.Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitorsRUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarctionDrug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.A small molecule that inhibits OGT activity in cells.Aurora B kinase is a potent and selective target in MYCN-driven neuroblastomaSelective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemiaA Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.Cancer network activity associated with therapeutic response and synergism.Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages.A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor.Multiple A2E treatments lead to melanization of rod outer segment-challenged ARPE-19 cells.Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.Multiplexing high-content flow (HCF) and quantitative high-throughput screening (qHTS) to identify compounds capable of decreasing cell viability, activating caspase 3/7, expressing annexin V, and changing mitochondrial membrane integrity.Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screeningOvercoming adaptive therapy resistance in AML by targeting immune response pathways
P50
Q28553712-C46A5105-7C49-43A3-8CB1-6E7B714DE14EQ28833540-44DDCAA6-D584-4FF9-9C9F-2F055203B8B5Q28975212-5C9CF778-1DD6-45FA-AF48-2F22D7CEB3EAQ30364972-77A815CF-C8C7-4B5F-8CEC-989494D618D9Q30402235-642806DE-E18A-4D35-ADE6-890D9CB42FF0Q30740300-F171FD8D-C96C-41D7-B89B-C78BDBA0F6E8Q34025327-D3B3E853-A60E-4747-A08F-83B0991E5D88Q34267671-3451105F-BE6D-4C26-82C9-A0FB18C04717Q34501206-EB512C46-AD8F-4450-B293-3C2B891FF1B5Q35573689-7886A050-FF2A-4F3C-823D-28300BAB5D4AQ35819646-665664FD-FE16-47F5-BD8D-DE833E3368DCQ36155080-F0DB01F3-F0C3-410F-B860-FCBD97A0B712Q36193086-D45F820E-032B-42EE-BE08-7039E7E0DCFCQ36583683-8AF106C2-0F58-4DE0-9DA9-0E9DD26D2276Q37199267-AF68DD72-B295-47B9-8669-9236A3191981Q37544085-C9125F14-4769-4535-90C6-BC7B97668D4CQ37633983-CB7B43FC-ED07-47BA-ABAC-2430609C4C81Q37639380-637A383C-7C03-4DC4-8C6E-ACC0D6B7068AQ38740932-CEC35EAD-FA8F-49B7-9E3C-D88675C06A81Q40182586-4EC94860-BD51-494B-AB6C-603BEBB549B3Q50421625-91B63661-D230-4AB1-B3EC-7378A05CD8A4Q54372681-CEA838BC-B2C8-455D-A4E9-521AB54763C3Q91360460-0CCCA0D4-790C-4F92-AAF5-F4CB1810E6AFQ93105342-3D6462F9-DB6A-4341-B5F7-CEB55B435588
P50
description
researcher (ORCID 0000-0001-9386-9001)
@en
wetenschapper
@nl
name
Craig J Thomas
@en
Craig J Thomas
@nl
type
label
Craig J Thomas
@en
Craig J Thomas
@nl
prefLabel
Craig J Thomas
@en
Craig J Thomas
@nl
P31
P496
0000-0001-9386-9001